skip to main content

    Updated Visitor Guidelines

 

MENU

 

MDS Treatment Options

Treatment options for patients with myelodysplastic syndromes range from supportive care that helps relieve symptoms to aggressive treatment that may slow or prevent progression of the disease.

Three types of standard treatment are used:

MDS Symptoms and Diagnosis

Myelodysplastic syndromes often do not cause early symptoms and are sometimes found during a routine blood test. Other conditions may cause the same symptoms. A doctor should be consulted if any of the following problems occur:
  • Shortness of breath.
  • Weakness or feeling tired.
  • Easy bruising or bleeding.
  • Petechiae (flat, pinpoint spots under the skin caused by bleeding).
  • Fever or frequent infections.
  • Bone pain.

Diagnosis/Screening for Myelodysplastic syndromes

  • Physical exam and history:

MDS Risk Factors

Most of the time, doctors don't know the exact cause of MDS. A risk factor is anything that increases your chance of developing a disease such as cancer. But risk factors don't tell us everything. People that do not have any risk factors can still get the disease. Having a risk factor, or even several, does not mean that you will get the disease.

Sarcoma Survivor Stories

The content on this page has moved. To read survivorship stores, please visit the Survivorship section or Sharing Hope section in Living with Cancer.

Lung cancer clues found in downstream pathway

A new study from researchers at the University of Michigan Rogel Cancer Center sheds light on the KRAS pathway with a potential target that might have more success at stopping lung cancer growth.

U-M researchers get $1.5M grant to develop customized pancreatic cancer treatment

Media contact: Nicole Fawcett, 734-764-2220   |   Patients may contact Cancer AnswerLine™, 800-865-1125

ANN ARBOR, Mich. — One day, a pancreatic cancer patient will provide a blood sample and doctors will recommend treatments designed to target all the harmful cell’s in the individual’s tumor. This is the vision of pancreatic cancer researchers at the University of Michigan Rogel Cancer Center.

Researchers open ‘Pandora’s box’ of potential cancer biomarkers

Researchers at the University of Michigan Rogel Cancer Center analyzed the global landscape of a portion of the genome that has not been previously well-explored. This analysis opens the door to discovery of thousands of potential new cancer biomarkers.

What makes pancreatic cancer so aggressive? New study sheds light

Media contact:  Nicole Fawcett, 734-764-2220   |   Patients may contact Cancer AnswerLine, 800-865-1125

ANN ARBOR, Mich. – New research from the University of Michigan Rogel Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.

New sequencing technique reveals genetic clues to rare breast tumors

A new study characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.

Pages